HuR与环氧化酶-2在卵巢上皮性癌表达及相关性研究

目的 探讨HuR和环氧化酶(COX-2)与卵巢上皮性癌临床病理参数的关系及二者的相关性.方法 收集原发卵巢上皮性癌组织68例(卵巢上皮性癌组),交界性卵巢肿瘤10例(交界性卵巢肿瘤组),正常卵巢组织5例(正常卵巢组织组)行免疫组织化学染色SP法检测HuR与COX-2的表达及与临床病理参数的关系.结果 (1)HuR在卵巢上皮性癌胞核中阳性表达率为76.47%(52/68)明显高于交界性卵巢肿瘤胞核30.00%(3/10)和正常卵巢组织(正常卵巢组织无表达)(x2=18.873,P＜0.05);HuR在交界性卵巢肿瘤的表达与正常卵巢组织比较差异无统计学意义(P＞0.05).(2)HuR在卵巢上皮性癌和交界性卵巢肿瘤胞质中的阳性表达率分别为45.60%(31/68)、10.00%(1/10),正常卵巢组织无表达;胞质HuR在恶性卵巢肿瘤组织的表达与交界性卵巢肿瘤和正常卵巢组织比较差异有统计学意义(x2=7.999,P=0.018);胞质HuR在交界性卵巢肿瘤的表达与正常卵巢组织比较差异无统计学意义(P＞0.05).(3)临床分期Ⅲ、Ⅳ期胞质HuR的阳性表达率为56.09%(23/41),显著高于Ⅰ、Ⅱ期的29.63%(8/27),差异有统计学意义(x2=4.598,P=0.032).在组织学分级高分化、中分化、低分化胞质HuR的阳性表达率分别为10.00%(1/10)、46.67%(14/30)、57.14%(16/28),差异有统计学意义(x2=6.627,P=0.036).(4)COX-2在卵巢上皮性癌(67.64%)和交界性卵巢肿瘤(60.00%)的表达明显高于正常卵巢组织(0),在卵巢上皮性癌的表达与交界性卵巢肿瘤比较差异无统计学意义(P＞0.05);COX-2高表达与临床分期和淋巴结转移有关;(5)胞质HuR与COX-2在肿瘤中的表达呈正相关(x2=0.317,P=0.008).结论 HuR与COX-2在卵巢上皮性癌的表达明显增高,且胞质HuR的表达与COX-2的表达呈正相关,提示胞质HuR与COX-2的过表达可能与卵巢癌的发生发展密切相关.

Abstract：

Objective To detect the expressions of HuR and COX-2 in epithelial ovarian carcinoma,and investigate the correlation of HuR and COX-2 expression. In addition, we attempt to seek the pathway to prevent the occurrence and development of epithelial ovarian cancer by combined analysis of various clinicopathologic characteristics. Methods The expressions of HuR and COX-2 in 68 epithelial ovarian carcinoma, 10 borderline ovarian tumors and 5 normal ovarian tissues were examined by S-P immunohistochemical method. The relationship of HuR and COX-2 expressions with clinicopathologic parameterwere evaluated by correlation analysis. Results(1) The expression of HuR in epithelial ovarian cancer tissue (76. 47% ,52/68) was significantly higher than that in borderline epithelial ovarian tumor tissues (30. 00% ,3/10) and normal ovarian tissues (0, x2 = 18. 873, Ps ＜ 0. 05), but there were no significant differences betweenthe expressions of HuR in borderline epithelial ovarian tumor and normal ovarian tissue(P ＞ 0. 05).(2) The positive expression rate of cytoplasmic HuR in epithelial ovarian carcinoma and borderline epithelial ovarian tumor were 45.60% (31/68) and 10. 00% (1/10) respectively,but normal ovarian tissues showed no staining of HuR. We found no significant differences between the expression of cytoplasmic HuR in epithelial ovarian carcinoma and borderline epithelial ovarian tumor or normal ovarian tissue(x2 = 7. 999 ,P =0. 018).(3) The positive expression rate of cytoplasmic HuR in epithelial ovarian carcinoma of FIGO stage Ⅲ - Ⅳ was significantly higher than that of stage Ⅰ - Ⅱ(56. 09% vs. 29. 63%, x2 = 4. 598, P = 0. 032). The positive expression rates of cytoplasmic HuR in epithelial ovarian carcinoma of histological grade 1,2,3 were 10. 00%,46. 67% ,57. 14% respectively, which showed significant difference in the comparison among the three groups (x2 =6. 627 ,P =0. 036). (4) The positive expression rates of COX-2 in epithelial ovarian cancer (67. 64%)and borderline epithelial ovarian tumor tissues (60. 00%) were significantly higher than that in normal ovarian tissues (0, Ps ＜ 0. 05), but we found no significant difference in the comparison between the expression of malignant and borderline ovarian tumors. Statistical analysis showed that the positive expression rate of COX-2 in epithelial ovarian carcinoma was correlated with FIGO stage and lymph node metastasis. (5)There was a significantly positive correlation between cytoplasmic HuR and COX-2 expressions in epithelial ovarian carcinoma. Conclusion The expressions of HuR and COX-2 increased in the epithelial ovarian carcinoma, and the cytoplasmic expression of HuR was significantly correlated with the expression of COX-2. These results suggested that increased cytoplasmic expression of HuR and COX-2 expression might play important roles in the initiation and development of epithelial ovarian carcinoma.

The relationship between the expressions of HuR and COX-2 in epithelial ovarian carcinoma

Objective To detect the expressions of HuR and COX-2 in epithelial ovarian carcinoma,and investigate the correlation of HuR and COX-2 expression. In addition, we attempt to seek the pathway to prevent the occurrence and development of epithelial ovarian cancer by combined analysis of various clinicopathologic characteristics. Methods The expressions of HuR and COX-2 in 68 epithelial ovarian carcinoma, 10 borderline ovarian tumors and 5 normal ovarian tissues were examined by S-P immunohistochemical method. The relationship of HuR and COX-2 expressions with clinicopathologic parameterwere evaluated by correlation analysis. Results(1) The expression of HuR in epithelial ovarian cancer tissue (76. 47% ,52/68) was significantly higher than that in borderline epithelial ovarian tumor tissues (30. 00% ,3/10) and normal ovarian tissues (0, x2 = 18. 873, Ps ＜ 0. 05), but there were no significant differences betweenthe expressions of HuR in borderline epithelial ovarian tumor and normal ovarian tissue(P ＞ 0. 05).(2) The positive expression rate of cytoplasmic HuR in epithelial ovarian carcinoma and borderline epithelial ovarian tumor were 45.60% (31/68) and 10. 00% (1/10) respectively,but normal ovarian tissues showed no staining of HuR. We found no significant differences between the expression of cytoplasmic HuR in epithelial ovarian carcinoma and borderline epithelial ovarian tumor or normal ovarian tissue(x2 = 7. 999 ,P =0. 018).(3) The positive expression rate of cytoplasmic HuR in epithelial ovarian carcinoma of FIGO stage Ⅲ - Ⅳ was significantly higher than that of stage Ⅰ - Ⅱ(56. 09% vs. 29. 63%, x2 = 4. 598, P = 0. 032). The positive expression rates of cytoplasmic HuR in epithelial ovarian carcinoma of histological grade 1,2,3 were 10. 00%,46. 67% ,57. 14% respectively, which showed significant difference in the comparison among the three groups (x2 =6. 627 ,P =0. 036). (4) The positive expression rates of COX-2 in epithelial ovarian cancer (67. 64%)and borderline epithelial ovarian tumor tissues (60. 00%) were significantly higher than that in normal ovarian tissues (0, Ps ＜ 0. 05), but we found no significant difference in the comparison between the expression of malignant and borderline ovarian tumors. Statistical analysis showed that the positive expression rate of COX-2 in epithelial ovarian carcinoma was correlated with FIGO stage and lymph node metastasis. (5)There was a significantly positive correlation between cytoplasmic HuR and COX-2 expressions in epithelial ovarian carcinoma. Conclusion The expressions of HuR and COX-2 increased in the epithelial ovarian carcinoma, and the cytoplasmic expression of HuR was significantly correlated with the expression of COX-2. These results suggested that increased cytoplasmic expression of HuR and COX-2 expression might play important roles in the initiation and development of epithelial ovarian carcinoma.